Lessons from Canada's notice of compliance with conditions policy for the life-cycle regulation of drugs
{{output}}
Innovative health technologies are not well regulated under current pathways, leading regulators to adopt contextual, life-cycle regulatory models, which authorize drugs based on earlier clinical evidence subject to the conduct of post-market trials that confi... ...
